News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing in Malaysia's largest clinic operator to expand the healthcare business
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Sun Pharma's Dadra facility receives OAI status from US FDA
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Subscribe To Our Newsletter & Stay Updated
